Binding and retention of polycationic peptides and dendrimers in the vascular wall  by Sakharov, D.V. et al.
Binding and retention of polycationic peptides and dendrimers in
the vascular wall
D.V. Sakharova;b;c;1, A.F.H. Jiea, D.V. Filippovd, M.E.A. Bekkersa, J.H. van Booma,
D.C. Rijkend;
aGaubius Laboratory, TNO Prevention and Health, P.O. Box 2215, 2301 CE Leiden, The Netherlands
bInstitute for Cardiovascular Research, Vrije Universiteit, Amsterdam, The Netherlands
cCBLE, Utrecht University, Utrecht, The Netherlands
dLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands
Received 28 November 2002; revised 6 January 2003; accepted 7 January 2003
First published online 24 January 2003
Edited by Beat Imhof
Abstract Extracellular matrix (ECM) of tissues, vascular tis-
sue in particular, contains a high concentration of negatively
charged glycosaminoglycans (GAGs), which are involved in
the regulation of cell motility, cell proliferation and the regula-
tion of enzyme activities. Previously, we have shown that the
vascular ECM is capable of binding an extremely high concen-
tration of positively charged molecules, such as polylysine. Vas-
cular ECM can be used therefore as a substrate for binding and
retention of drugs delivered intravascularly, if these drugs are
endowed with an ability to bind to the vascular ECM. In this
study, we evaluated a number of positively charged molecules as
potential a⁄nity vehicles for delivery of drugs to the vascular
ECM. We labelled the molecules of interest with £uorescence
and compared them ex vivo in terms of binding and retention in
the de-endothelialised rat carotid artery after intravascular de-
livery under pressure. High molecular weight polylysine (84
kDa) and polyamidoamine (PAMAM) dendrimers accumulated
in the wall of the artery up to a concentration of 10 mg/ml and
were not washed away signi¢cantly after 4 h of perfusion of the
artery. A 24-mer peptide containing a consensus sequence for
binding to GAGs (ARRRAARA)3, 2.7 kDa, was comparable to
high molecular weight polylysine and dendrimers in terms of
binding and retention. A 14-mer GAG-binding peptide from
vitronectin and low molecular weight polylysine, 3 kDa, accu-
mulated in the vascular wall up to about 3 mg/ml and was
washed away after 30 min of perfusion. A 10-mer consensus
GAG-binding peptide did not bind signi¢cantly to the vascular
tissue. We conclude that the consensus 24-mer GAG-binding
peptide is by far superior to polylysine of a similar molecular
weight in terms of binding to vascular tissue, and can provide
high accumulation and long-term retention of a low molecular
weight compound (£uorescein, as a model molecule) in the vas-
cular wall. Rationally designed GAG-binding peptides can be
useful as a⁄nity vehicles for targeting drugs to the vascular
ECM.
6 2003 Federation of European Biochemical Societies. Pub-
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1. Introduction
Extracellular matrix (ECM) of the vascular tissue represents
an attractive target for therapeutic intervention. Proteogly-
cans are ubiquitous components of the ECM; their glycosa-
minoglycan (GAG) chains are involved in many biological
functions, including regulation of cell motility, cell growth,
and tissue morphogenesis [1]. GAGs represent about 2^5%
of the non-aqueous material of the vascular wall [1], and
consist of a negatively charged branched network with a pro-
found capacity for binding various molecules including
growth factors, factors involved in blood coagulation, lipid
metabolism etc. Most of these GAG-binding proteins contain
so-called GAG-binding consensus sequences of amino acids,
identi¢ed by Cardin and Weintraub [2] mainly on the basis of
molecular modelling. These sequences contain clustered pat-
terns of positive charge XBBXBX or XBBBXXBX, where B
represents a basic amino acid, and X represents an uncharged
or hydrophobic amino acid. Fromm et al. [3] have found
experimentally that a slightly di¡erent sequence is optimal
for binding of short peptides to GAGs. In particular, among
10-mer peptides containing a structure RRGmRR or
RRRGmR the peptide GRRRGGGRGG shows the highest
binding to heparan sulphate.
In a previous paper, we have shown that high molecular
weight, positively charged molecules, like polylysine and poly-
amidoamine (PAMAM) dendrimers, can be accumulated in
the vascular tissue up to the concentration of 10 mg/ml and
retained within the vascular wall in vivo up to several days [4].
This o¡ers a possibility of using positively charged GAG-
binding molecules as a⁄nity vehicles for drug targeting.
Such an approach could work in combination with local intra-
vascular delivery via catheter-based devices or via eluting
stents [5,6].
The possibility of using highly charged polylysine-like mol-
ecules for in vivo applications, like gene targeting and others
[7,8], is being actively investigated. However, in vivo applica-
tions of polylysine are likely to be limited because the ex-
tremely high charge is associated with toxicity [9,10]. For
the purpose of drug targeting to GAG-containing ECM, poly-
peptides comprising GAG-binding consensus sequences may
be a better choice, since they have a lower average charge
density.
In this paper, we compare a number of molecules including
polylysine, dendrimers, and a number of consensus GAG-
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binding peptides in terms of their binding and retention in a
model of intravascular delivery. We show that a 24-mer, but
not a 10-mer, consensus peptide is comparable to large poly-
lysine and dendrimer molecules in terms of intravascular bind-
ing and retention.
2. Materials and methods
2.1. Materials
Fluorescein isothiocyanate (FITC), £uorescein-5-maleimide, N-suc-
cinimidyl-S-acetylthioacetate (SATA), were from Pierce. Poly-L-lysine
(3 kDa and 84 kDa), as well as bovine albumin, were obtained from
Sigma. Starburst1 PAMAM dendrimers (generations 4 and 5) were
purchased from from Aldrich. The peptides were synthesised by Euro-
sequence, Groningen, The Netherlands. A peptide GRRRGGGRGG-
amide containing one consensus sequence for binding to GAGs [2,3]
and the GAG-binding 14-mer peptide from vitronectin with the se-
quenceKKQRFRHRNRKGYR [11] were both synthesised with an ad-
ditional cysteine on the N-terminus. The long consensus sequence pep-
tide (ARRRAARA)3 [12] was synthesised with an additional alanine at
the N-terminus, modi¢ed with SATA, which introduces a protected SH-
group. A random 12-mer peptide GPYSGEPKPFSA £anked with cys-
teine on the N-terminus was used as a negative control.
2.2. Labelling with £uorescein derivatives
Polylysines and dendrimers at a concentration of 5 mg/ml in a
bu¡er containing 30 mmol/l sodium bicarbonate and 140 mmol/l
NaCl, pH 9.2, were incubated for 1 h in the dark with FITC at a
¢nal concentration of 250 WM. The cysteine-containing peptides (the
short consensus peptide and the GAG-binding peptide from vitronec-
tin) at 0.5 mM in Tris-bu¡ered saline (TBS), containing 1 mM EDTA,
were incubated with £uorescein-5-maleimide at 1 mM for 1 h, and
unreacted groups were blocked with 5 mM N-ethylmaleimide. The
SATA-containing long consensus sequence peptide was labelled with
£uorescein-5-maleimide under the same conditions after deprotection
of SH-groups (incubation with 0.5 M hydroxylamine HCl for 2 h,
according to a Pierce protocol). To separate the unbound dye from
the labelled molecules we used gel ¢ltration on Sephadex G-25 for
large molecules (polylysine 84 kDa and dendrimers), whereas for the
peptides we used either CM^Sepharose ion-exchange chromatography
with elution by a gradient of NaCl, or reverse-phase high-performance
liquid chromatography.
2.3. Ex vivo intravascular delivery of labelled molecules into rat carotid
artery
A segment (approximately 1.2 cm) of the common carotid artery
was removed from an anaesthetised rat and kept for not longer than
1 h in colourless RPMI cell culture medium at 4‡C before the experi-
ment. The labelled molecules were delivered into such a segment,
Fig. 1. Binding and retention of £uorescein-labelled molecules in the rat carotid artery after intravascular delivery under pressure. Fluorescence
images of 20 Wm thick cross-sections of arteries. A: Starburst dendrimer, generation 5, immediately after delivery (left) and after 4 h of perfu-
sion with cell culture medium (right). B: consensus peptide (ARRRAARA)3 immediately after delivery (left) and after 4 h of perfusion (right).
C: 3 kDa polylysine immediately after delivery (left) and after 30 min of perfusion (right). Bar= 100 Wm.
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using the technique and conditions described elsewhere [4]. Brie£y,
one end of the vessel was secured on a plastic tube connected to a
needle attached to a syringe equipped with a manometer. To remove
any remaining blood and to destroy the endothelium, the vessel was
rinsed with a few millilitres of RPMI and pumped through with air
for 5 min with a peristaltic pump. Then, the vessel was ¢lled in with
RPMI, containing a labelled compound at 1 mg/ml, the open end of
the vessel was closed with an atraumatic vascular clamp, and a pres-
sure of 0.35 atm was applied for 20 min. Then, the clamp was re-
moved, the vessel was brie£y washed with RPMI, the distal half of the
vessel was removed and snap-frozen. The proximal part of vessel, still
connected to the needle, was perfused with RPMI through a peristal-
tic pump. After the desired time periods, the proximal half of the
vessel was cut o¡ and snap-frozen in a similar way.
2.4. Visualisation and quanti¢cation of the bound molecules
From the frozen pieces of the vessels, 20 Wm cross-sections were
prepared, dried and viewed under a £uorescence microscope. In order
to quantify the local concentration of £uorescence-labelled molecules
within the vascular wall, the sections were eluted with TBS, to which
NaCl had been added to a ¢nal concentration of 2 M. The amount of
£uorescence in the eluate was measured with an LS50B spectro£uo-
rometer (Perkin-Elmer), and the amount of eluted £uorescence-la-
belled compound was determined using a calibration curve obtained
with dilutions of the compound. The local concentration of bound
£uorescence-labelled compound was calculated as the ratio of the
amount of eluted compound and the volume of the section of the
vessel, which was typically saturated with £uorescence throughout
the whole depth of the vessel wall. The volume was calculated as a
product of the thickness of the section (20 Wm), the perimeter of the
vessel and the width of the vessel wall. For each compound, the
experiments were performed in duplicate. From each specimen corre-
sponding to a particular perfusion time, at least six sections were
prepared and used for quanti¢cation of binding.
3. Results
Using the model of intravascular delivery under pressure
[4], we studied binding and retention of the following mole-
cules in the vascular wall of the de-endothelialised rat carotid
artery: high and low molecular weight polylysine (84 kDa and
3 kDa, respectively) ; PAMAM Starburst dendrimers of gen-
erations 4 and 5 (14 and 28 kDa, respectively) ; a 24-mer pep-
tide, containing three copies of a consensus sequence for bind-
ing to GAGs, (ARRRAARA)3 ; a 10-mer consensus peptide,
GRRRGGGRGG; a 14-mer GAG-binding peptide from vi-
tronectin, KKQRFRHRNRKGYR; and a control random
10-mer peptide.
Fig. 1 shows typical examples of the distribution of intra-
vascularly delivered molecules in the wall of the rat carotid
artery. PAMAM dendrimer, generation 5, and low molecular
weight polylysine (3 kDa) exemplify molecules exhibiting, re-
spectively, strong and weak binding to the vascular wall. The
dendrimer bound to the tissue strongly and the amount of
bound dendrimer remained virtually unchanged after 4 h of
perfusion. The initial binding of low molecular weight poly-
lysine was much weaker, and it was completely washed out
already after 30 min of perfusion. The 24-mer consensus pep-
tide, (ARRRAARA)3, although a smaller molecule than poly-
lysine, exhibited much stronger binding and retention, com-
parable to those of the dendrimer.
Most of the bound £uorescent material could be eluted
from the sections by incubation of the sections with 2 M
NaCl (Fig. 2). By measuring the amount of £uorescence
eluted from the sections, we could quantify the amount of
£uorescent molecules bound to the vascular wall and follow
the kinetics of the wash-out of these molecules out of the
vessel wall during 4 h of perfusion (Fig. 3). Consistent with
our previously published data [4], 84 kDa polylysine and PA-
MAM dendrimer (generation 5, 28 kDa) were accumulated in
the vascular wall up to a concentration of about 10 mg/ml and
Fig. 2. Elution of bound £uorescein-labelled consensus peptide, (ARRRAARA)3, from 20 Wm thick cross-sections of a rat carotid artery. After
intravascular delivery of the peptide under pressure, 20 Wm thick cross-sections of the artery were prepared and eluted for 10 min either with
PBS (left) or with phosphate bu¡er containing 2 M NaCl. Bar= 100 Wm.
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Fig. 3. Binding and retention of £uorescein-labelled molecules in the
rat carotid artery. After intravascular delivery under pressure, the
vessels were perfused with cell culture medium for the indicated pe-
riods of time. Bound £uorescence was eluted from the cross-sections
of the artery and quanti¢ed in a spectro£uorometer. 84 kDa poly-
lysine (O), PAMAM dendrimer generation 5 (P), long consen-
sus peptide (ARRRAARA)3 (R), GAG-binding peptide from vitro-
nectin (F), 3 kDa polylysine (a), short consensus peptide
GRRRGGGRG-amide (8).
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were not noticeably washed out after 4 h of perfusion. PA-
MAM dendrimer generation 4 (14 kDa) behaved essentially
similarly (data not shown). The 10-mer consensus peptide did
not accumulate at all in the vascular wall, similarly to a ran-
dom 12-mer control peptide (data not shown). The 14-mer
GAG-binding peptide from vitronectin and 3 kDa polylysine
showed moderate accumulation (about 3 mg/ml) immediately
after intravascular delivery, but after 30 min of perfusion they
were completely washed out. Finally, the 24-mer consensus
peptide (ARRRAARA)3, 2.7 kDa, showed binding and reten-
tion comparable to those of high molecular weight polylysine
and dendrimers.
4. Discussion
Local intravascular delivery of drugs is an active area of
research in interventional cardiology and vascular medicine.
Either local drug delivery catheters or eluting stents can be
used for topical delivery of a drug to a desired segment of a
blood vessel [5,6]. E⁄ciency of local delivery, penetration and
distribution of the drug in the vascular wall, and retention
after delivery are important parameters being studied both
experimentally and theoretically [4,13^15]. Binding of a drug
to components of the vascular wall is important for both
increasing the e⁄ciency of delivery (i.e. the fraction of the
drug which leaves the catheter or eluting stent and is depos-
ited in the vessel wall) and prolongation of the drug retention
in the vascular wall. In our previous experimental and theo-
retical studies, we have shown that molecules incapable of
binding to the vascular wall will be washed out by the blood-
stream in a matter of minutes [4,15]. Some hydrophobic mol-
ecules, the potential anti-proliferative agent paclitaxel in par-
ticular, have been shown to interact with insoluble elements of
vascular tissue, which results in prolonging the retention after
delivery via an eluting stent [16]. Hydrophilic molecules, pep-
tides and proteins in particular, are also being examined as
potential drugs [13,17,18]. We have shown that positively
charged hydrophilic molecules (polylysine, in particular) will
be retained in the vascular wall for many hours after local
delivery both in an ex vivo perfusion system and in vivo after
restoration of the bloodstream [4]. Cationic derivatives of
antioxidant enzymes, obtained by coupling the enzymes to
polylysine, were also shown to be retained ¢rmly in articular
tissue and to suppress in£ammatory response in an animal
model of arthritis [19]. Tissue proteoglycans, which contain
negatively charged GAG chains, are the most likely binding
counterparts for cationic macromolecules.
In vivo applications of polylysine are limited due to its
toxicity [9,10]. Modi¢cation of polylysine by partially block-
ing its positive charge with various groups has been shown to
reduce its toxicity [7,20]. Synthetic polycationic dendrimers
are being intensively studied for the same type of applications
[21]. Dendrimers are highly branched spherical macromole-
cules with all bonds emanating from the central core. The
size of dendrimer is determined by its generation number,
i.e. the number of repetitions of a two-step reaction used for
its synthesis. Although the dendrimers have a number of at-
tractive features for applications in pharmaceutical chemistry,
they still exhibit a considerable toxicity [22]. Using positively
charged consensus peptides, which imitate naturally occurring
GAG-binding sequences, is an alternative approach.
In the present paper, we studied how relatively short con-
sensus GAG-binding peptides bind to and are retained within
vascular tissue. Papers published earlier by others on the in-
teraction between consensus peptides and GAGs (mostly hep-
arin) either describe interaction of peptides with GAGs in
terms of elution of the peptides from heparin^Sepharose
with increasing ionic strength, or assess the Kd of interaction
in bu¡ers with non-physiologically low ionic strength [3,23].
In a recent paper of Verrecchio et al. [12], the interaction of
consensus peptides with heparin was studied by a⁄nity co-
electrophoresis in a bu¡ered sodium acetate solution. Here,
we looked at binding of charged peptides directly to the vas-
cular tissue using a model of intravascular delivery under
pressure in rat carotid artery.
The results indicate that short peptides, containing a single
GAG-binding consensus sequence, do not bind noticeably to
the vascular tissue. In contrast, a peptide containing a linear
trimer of a consensus sequence demonstrates an amount of
binding and retention comparable to those of high molecular
weight polycations (polylysine and dendrimers). Polylysine of
the same molecular weight (3 kDa) exhibited a much weaker
binding, indicating that consensus peptides indeed have an
optimal spatial charge distribution providing maximal binding
to GAGs in tissues. Our results are consistent with a⁄nity co-
electrophoresis data of Verrecchio et al. [12], who have shown
that for consensus peptides XBBBXXBX each step from
monomer to dimer and from dimer to trimer results in a
drastic increase in a⁄nity to heparin. Further increase in
length of the consensus peptides (to 4- and 5-mers) resulted
in only moderate if any further increase in a⁄nity [12].
In conclusion, this paper demonstrates that relatively low
molecular weight oligomers of GAG-binding consensus pep-
tides bind considerably to the vascular tissue, and can there-
fore potentially be used as a⁄nity vehicles for drug delivery.
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